EC Number   |
Inhibitors |
Structure |
|---|
   3.4.22.71 | morin |
IC50 for recombinant SrtB(DELTA30): 0.00854 mM, no antibacterial activity against Staphylococcus aureus |
   |
| 3.4.22.71 | myricetin |
IC50 for recombinant SrtB(DELTA30): 0.03689 mM, no antibacterial activity against Staphylococcus aureus |
|
| 3.4.22.71 | phloretin |
compound shows little anti-Staphylococcus aureus activity, but significantly inhibit SrtB activity in vitro. Phloretin reduces human alveolar epithelial cell damage caused by Staphylococcus aureus. Phloretin directly localizes in the active pocket of SrtB and blocks substrate binding |
|
| 3.4.22.71 | psammaplin A1 |
potential of this inhibitor for the treatment of Staphylococcus aureus infections |
|
| 3.4.22.71 | quercetin |
IC50 for recombinant SrtB(DELTA30): 0.03328 mM, no antibacterial activity against Staphylococcus aureus |
|
| 3.4.22.71 | quercetin-3,3'-dimethyl ether |
IC50 for recombinant SrtB(DELTA30): 0.0603 mM, no antibacterial activity against Staphylococcus aureus |
|
